The Ideal Pharma Country Manager: South Korea (Egon Zehnder)
Examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Here, Eugene Kim, Seoul office leader of executive…
Address: Room A-101, Namsong Bldg., 260-199 Itaewon-dong, Yongsan-gu Seoul, 140-200, Republic of Korea
Tel: +82 2 796 1056
Web: http://crm.cegedim.com/Pages/default.aspx
Cegedim was created in 1969 by Jean-Claude Labrune, a French visionary entrepreneur who focused on the pharmaceutical industry to provide companies with tailored services that help them build successful commercial strategies. In the late 70’s the first Customer Relationship Management solution designed for the Pharmaceutical industry was launched in France and quickly became a standard. With the success of its solutions, Cegedim quickly expanded its business internationally. In May 2007, Cegedim reinforced its global presence and leadership with the acquisition of Dendrite International, a US based company leading the SFA business in the healthcare sector on its continent as well as in Asia. This successful integration gave birth to a uniquely capable global entity providing Life Sciences ready CRM solutions. Today the new company renamed Cegedim Relationship Management does business in over 80 countries and accounts for more than 50 percent of the Cegedim Group’s annual revenues of $1.1 billion. Around the world, Cegedim Relationship Management works with companies behind the scenes to develop the most appropriate solutions that effectively manage the complex regulatory environment, minimize risks and decrease costs. Laurent Labrune, Group founder’s son, is the Chief Executive Officer of the new global organisation since 2007. He brought a wealth of creativity, innovation and expertise with a strong and knowledgeable management team. Altogether, they effectively made strategic choices for the long term leadership of the company.
Examining what it takes to be a country manager of a multinational pharma company in some of the world’s most challenging markets. Here, Eugene Kim, Seoul office leader of executive…
Rana Azfar, vice-president & general manager of Novo Nordisk Korea offers his impressions of the Korean market since moving from Pakistan. Azfar discusses how the most innovative insulin products have…
Young-Woo Park, CEO of Y-Biologics – renowned for their library with diversity of 1011 – unveils their plan to be the first in Korea to develop the PD-1 antibody as…
Yong Zu Kim, founder and CEO of Lego Chem, discusses his company’s two areas of focus, anti-infectives and antibody drug conjugates. Dr Kim explains how his strategy has changed from…
Kyoung-June Lee, CEO of JW CreaGene, lifts the lid on their novel technology of developing an immuno-oncology treatment from dendritic cells, which act as a command centre of the immune…
Dr BG Rhee, CEO of SCM Lifescience discusses their patented proprietary subfraction technology to extract high purity cell cultures, and the impact this will have on the efficacy, cell differentiation…
Professor Jong In Lim, cyber security specialist and president of the Institute for Cyber Security and Privacy (ICSP) provides his assessment of the current situation for information security in Korea,…
Deborah Chee, President of KoNECT (Korea National Enterprise for Clinical Trials), discusses what it takes to build one of the world’s leading clinical trials ecosystems and highlights the importance of…
Hakhyun Nam, co-founder and CTO at i-SENS, Inc. a developer of glucose sensor devices, reveals his path to running a globally successful medical devices company, and how i-SENS overcame early…
Julien Samson, vice president and general manager of GSK Korea explains how GSK’s new global strategy is being delivered within the Korean affiliate. Mr Samson explains the focus areas for…
As the 3rd largest pharma region in Asia, Korea’s booming pharma industry owes much to its mass of family-run conglomerates known as Chaebol. It comes as no surprise to find tech…
Shingyu Bae, CEO of MDimune, explains how the company’s new exosome drug delivery system increases efficacy and reduces toxicity compared with other oncology products. He also discusses the potential and…
See our Cookie Privacy Policy Here
